Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Interest & Investment Income (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Interest & Investment Income data on record, last reported at $5.9 million in Q4 2023.

  • For Q4 2023, Interest & Investment Income changed N/A year-over-year to $5.9 million; the TTM value through Dec 2023 reached $21.6 million, changed N/A, while the annual FY2024 figure was $29.7 million, 37.14% up from the prior year.
  • Interest & Investment Income reached $5.9 million in Q4 2023 per CGEM's latest filing, up from $5.9 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $5.9 million in Q4 2023 and bottomed at $49000.0 in Q1 2021.
  • Average Interest & Investment Income over 4 years is $1.7 million, with a median of $221500.0 recorded in 2020.
  • Peak YoY movement for Interest & Investment Income: tumbled 87.04% in 2021, then surged 2188.32% in 2023.
  • A 4-year view of Interest & Investment Income shows it stood at $79000.0 in 2020, then skyrocketed by 73.42% to $137000.0 in 2021, then soared by 408.76% to $697000.0 in 2022, then soared by 748.92% to $5.9 million in 2023.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $5.9 million in Q4 2023, $5.9 million in Q3 2023, and $5.3 million in Q2 2023.